FUNDAMENTALS · Fundamentals · US Healthcare

Taysha Gene Therapies (TSHA) Fundamentals 2026 — Revenue Analysis | SniperIQ

Taysha Gene Therapies (TSHA) is a US-listed Healthcare company in Biotechnology with a market capitalization of

.4B, trading at $5.58 on the NASDAQ. This SniperIQ fundamentals page covers Taysha Gene Therapies's valuation, profitability (net margin -1738.4%), revenue (
0M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap
.4B
Net Margin-1738.4%
Revenue (FY25)
0M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Taysha Gene Therapies's market cap?

Taysha Gene Therapies (TSHA) has a market capitalization of approximately

.4B, trading at $5.58 on the NASDAQ. Market cap moves with the live share price.

What is Taysha Gene Therapies's P/E ratio?

Taysha Gene Therapies's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 9.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Taysha Gene Therapies?

Taysha Gene Therapies runs a net profit margin of -1738.4%, a gross margin of 88.2%, and an operating margin of -1774.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Taysha Gene Therapies generate?

Taysha Gene Therapies reported revenue of

0M for fiscal year 2025, with net income of -
09M and earnings per share (EPS) of -0.34. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Taysha Gene Therapies pay a dividend?

Taysha Gene Therapies does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Taysha Gene Therapies financially healthy?

Taysha Gene Therapies carries a debt-to-equity ratio of 0.08x and a current ratio of 14.04x, with a market beta of 1.16. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Taysha Gene Therapies a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Taysha Gene Therapies (TSHA) the key facts are: market cap

.4B, revenue
0M, 52-week range 2.525-7.3. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Taysha Gene Therapies's full fundamentals live

Get Taysha Gene Therapies's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Thomson Medical Group (A50) fundamentals · Absci (ABSI) fundamentals · ArriVent BioPharma (AVBP) fundamentals · Phibro Animal Health (PAHC) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons